Identification of molecular subtypes based on chromatin regulator and tumor microenvironment infiltration characterization in papillary renal cell carcinoma

Tang, Qilin; Pan, Deshen; Xu, Chaoliang; Chen, Lei

doi:10.1007/s00432-022-04482-4

Cited by 4 publications

(5 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Renal cell carcinoma has long been regarded as a kind of tumor immunogenicity and participates in a variety of immune cells in the tumor microenvironment mediated antitumor immune response [35]. We found that CCNB1 was positively correlated with B lymphocytes CD8 + T lymphocytes and dendritic cells, and negatively correlated with macrophages in the tumor microenvironment through the TIMER database.…”

Section: Drug Sensitivity Screening and Molecular Dockingmentioning

confidence: 79%

Bioinformatics analysis highlights CCNB1 as a potential prognostic biomarker and an anti-kidney renal papillary cell carcinoma drug target

Gong

2023

Preprint

View full text Add to dashboard Cite

Kidney renal papillary cell carcinoma (KIRP) is a common tumor in the urinary system, which is easy to cause lymph node invasion. Once metastatic, the prognosis is poor, and there is a lack of effective early diagnostic markers for this tumor. We used R language to process the data from TCGA and GTEx combined with multiple online databases. Sensitive drugs targeting CCNB1 were screened out by the ‘pRRophetic’ package and molecular docking technology. Our data indicated that the expression level of CCNB1 in KIRP was significantly higher than that in normal tissues. This result was validated at the IHC level through the HPA database. In addition, the CCNB1 was also significantly increased with the progression of the T and M stages. The patients with higher CCNB1 expression had a poor prognosis in KIRP. CCNB1 was also an independent prognostic factor for KIRP. What’s more, CCNB1 was associated with immune infiltration. Finally, we also screened out five drugs targeting CCNB1. Our results showed that CCNB1 is a potential and reliable diagnostic biomarker for KIRP and it is a good predictor of KIRP survival. The five selected drugs targeting CCNB1 may bring good social value to patients with KIRP metastasis.

show abstract

Section: Drug Sensitivity Screening and Molecular Dockingmentioning

confidence: 79%

Bioinformatics analysis highlights CCNB1 as a potential prognostic biomarker and an anti-kidney renal papillary cell carcinoma drug target

Gong

2023

Preprint

View full text Add to dashboard Cite

show abstract

“…A previous study also demonstrated that CCNB1 is mainly involved in cell cycle and DNA replication pathways. [34] GSEA indicated that CCNB1 was associated with multiple pathways, including ECM_RECEPTOR_INTERACTION, FOCAL_ADHESION, DILATED_CARDIOMYOPATHY, and REGULATION_OF_ACTIN_CYTOSKELETON. Renal cell carcinoma has long been regarded as an immunogenic tumor that participates in a variety of immune cells in the tumor microenvironment-mediated antitumor immune response.…”

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Bioinformatics analysis highlights CCNB1 as a potential prognostic biomarker and an anti-kidney renal papillary cell carcinoma drug target

Gong,

et al. 2024

Medicine

View full text Add to dashboard Cite

Kidney renal papillary cell carcinoma (KIRP) is a common urinary tumor that causes lymph node invasion. Once metastatic, the prognosis is poor and there is a lack of effective early diagnostic markers for this tumor. The expression of CCNB1 in KIRP tumor tissues was significantly higher than that in normal tissues in The Cancer Genome Atlas database with or without the genotype-tissue expression database, and a consistent result was obtained in 32 paired tissues. In addition, CCNB1 expression increased remarkably with the progression of the T and M stages. Moreover, using the online HPA database, we verified that the immunohistochemical scores of CCNB1 in KIRP were higher than those in the normal kidney tissues. The higher expression group of CCNB1 showed a worse prognosis in KIRP. Moreover, the receiver operating characteristic curve, univariate and multivariate analyses, and construction of the column diagram further illustrated that CCNB1 was an independent prognostic factor for KIRP. Meanwhile, CCNB1 could better predict the 1- and 3-year survival rates of KIRP. Six genes were significantly and positively co-expressed with CCNB1. We also found that the CCNB1 high-expression group was enriched in the ECM_RECEPTOR_INTERACTION and FOCAL_ADHESION pathways. Finally, drug sensitivity analysis combined with molecular docking identified 5 targeting drugs with the strongest binding activity to CCNB1. CCNB1 is a potential and reliable biomarker for KIRP diagnosis and can be used to predict the survival of patients with KIRP. The 5 selected drugs targeting CCNB1 may provide new hopes for patients with KIRP metastasis.

show abstract

“…A two-in-one nanoprodrug improves chemosensitivity in prostate cancer cells through increased apoptosis and metastasis inhibition [ 33 ]. PPARG also contributes to cell cycle dysregulation, related to chemosensitivity [ 34 , 35 ], and influences drug detoxification processes, affecting chemotherapy efficacy [ 36 , 37 ]. Moreover, PPARG's involvement in the inflammatory response is critical for determining chemosensitivity [ 38 , 39 ].…”

Section: Discussionmentioning

confidence: 99%

PPARG and the PTEN-PI3K/AKT Signaling Axis May Cofunction in Promoting Chemosensitivity in Hypopharyngeal Squamous Cell Carcinoma

Han,

Chen,

Chen

et al. 2024

PPAR Research

View full text Add to dashboard Cite

It has been demonstrated that PPARG may interact with the PTEN-PI3K/AKT pathway, contributing to its involvement in the chemotherapy treatment of hypopharyngeal squamous cell carcinoma (HSCC). However, the underlying mechanism remains largely unknown. In this study, gene expression profiles of 17 HSCC patients, comprising 8 chemotherapy-sensitive patients (CSP) and 9 chemotherapy-nonsensitive patients (CNSP), were collected and analyzed to investigate expression patterns, correlations, influencing factors of the PPARG-PTEN-PI3K/AKT pathway, and its role in regulating chemosensitivity. The results revealed significantly increased expression (p<0.04) of AKT1, AKT2, AKT3, PIK3CA, PPARG, and PTEN in the CSP group compared to the CNSP group. Specifically, AKT2 exhibited significant overexpression in tumor tissue (p=0.01), while AKT2, AKT3, PPARG, and PTEN displayed significant increases in normal tissue (p≤0.04). Positive correlations (R∈0.43,0.71, p<0.014) were observed between PIK3CA, AKT1, AKT2, AKT3, and PTEN, with AKT2, AKT3, and PTEN also showing significant correlations with PPARG (R∈0.35,0.47, p<0.04). Age, gender, and disease stage had no influence on PPARG, PIK3CA, and PTEN expression, but they may affect AKT expressions. Pathway analysis revealed that PPARG may interact with the PTEN-PI3K/AKT signaling pathway, playing a crucial role in regulating chemosensitivity in the normal tissue microenvironment. Our results suggest that AKT1 and PIK3CA may be associated with chemosensitivity in HSCC tumor cells, while PPARG and PTEN might exhibit a correlation with a specific segment of the PI3K/AKT pathway, potentially influencing chemosensitivity in the normal tissue microenvironment of HSCC patients.

show abstract

Identification of molecular subtypes based on chromatin regulator and tumor microenvironment infiltration characterization in papillary renal cell carcinoma

Cited by 4 publications

References 46 publications

Bioinformatics analysis highlights CCNB1 as a potential prognostic biomarker and an anti-kidney renal papillary cell carcinoma drug target

Bioinformatics analysis highlights CCNB1 as a potential prognostic biomarker and an anti-kidney renal papillary cell carcinoma drug target

Bioinformatics analysis highlights CCNB1 as a potential prognostic biomarker and an anti-kidney renal papillary cell carcinoma drug target

PPARG and the PTEN-PI3K/AKT Signaling Axis May Cofunction in Promoting Chemosensitivity in Hypopharyngeal Squamous Cell Carcinoma

Contact Info

Product

Resources

About